An interventional study of enVast stent and conventional treatment in Segment Elevation Myocardial Infarction (STEMI), sponsored by Vesalio. Active, not recruiting at 11 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-19.
Sponsored by Vesalio · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 71 studies in ST Elevation Myocardial Infarction with a site in Italy — 14 open to participants now, 17 under way, 1 of them phase 3. ST Elevation Myocardial Infarction · Italy.
Among the 71 studies in ST Elevation Myocardial Infarction with a site in Italy, this one is the 22nd largest by planned enrollment of the 42 interventional ones that give a count, is one of 2 that started in 2021, is one of 17 with no phase, reaches primary completion later than 7 of the 16 other live ones, and was the 52nd registered.
855 studies on the registry are indexed under ST Elevation Myocardial Infarction; 201 are open to participants now.
Browse ST Elevation Myocardial Infarction studies →14 of the 71 studies in ST Elevation Myocardial Infarction with a site in Italy are open now. Recruiting first, the newest first:
Ceric Sàrl · Sites in Italy
Ages 18–75
Federico II University · Sites in Italy
Ages 18–80
CorFlow Therapeutics AG · Sites in Italy, United States, Lithuania and 2 more countries
Ages 18+
Azienda Ospedaliera "Sant'Andrea" · Sites in Italy
Ages 18+
University of Pisa · Sites in Italy
Healthy volunteers
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 124 ST Elevation Myocardial Infarction studies recruiting now, 78 (63%) set no upper age limit and 20 (16%) stop at 75 or younger; 10 take children under 18; 9 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
71 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 2 · Phase 3 10 · Phase 4 14
First in 2003; this study’s year is marked. 2 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 148 is below the median of 194 across 531 interventional studies indexed under ST Elevation Myocardial Infarction.
Median enrollment 174 across the 42 interventional studies, 350 across the 29 observational. Of the 32 that completed or were terminated, 7 (22%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 71 have an industry lead sponsor. The 10 most frequent:
Vesalio is the lead sponsor of 9 studies on the registry; 2 are open to participants now.
Vesalio has 1 study filed under ST Elevation Myocardial Infarction — fewer than ten, so there is no comparison to draw.
7 of the studies in ST Elevation Myocardial Infarction with a site in Italy that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06965023Azienda Ospedaliera "Sant'Andrea"Microplastics and Nanoplastics (MNPs) in Patients With ST-elevation Myocardial Infarction (STEMI) | 2026-12-30 |
| NCT06909578CorFlow Therapeutics AGMicrovascular Obstruction Diagnosis Using the CoFI™ System Assessment - II | 2026-12-31 |
| NCT06887413Ceric SàrlTACTIC Coronary Thrombus Aspiration With Cath Rx In Anterior Myocardial Infarction: A Randomized Control Trial. | 2027-02-28 |
| NCT07176104Raffaele MarfellaFunctional Milk Supplementation to Reduce In-Stent Restenosis in STEMI Patients (SMASOEA Trial) | 2027-06 |
| NCT07598565University of Roma La SapienzaThe CORE - μFR Clinical Trial | 2027-06-25 |
Add all 7 to your calendar (.ics) → With an account.
Among the 71 studies in ST Elevation Myocardial Infarction with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is designed to compare the safety and effectiveness of blood clot (thrombus) removal in subjects presenting with ST-segment elevation myocardial infarction (STEMI) with the enVast coronary system versus conventional intervention.
A prospective, multi-center, randomized clinical trial designed to assess the safety and effectiveness of the enVast coronary thrombectomy system as an adjunctive measure to conventional intervention in subjects presenting with ST-segment elevation myocardial infarction (STEMI).
855 studies on the registry are indexed under ST Elevation Myocardial Infarction; 201 are open to participants now.
This study's planned enrollment of 148 is below the median of 194 across 531 interventional studies indexed under ST Elevation Myocardial Infarction.
Browse ST Elevation Myocardial Infarction studies →Vesalio is the lead sponsor of 9 studies on the registry; 2 are open to participants now.
Compared within ST Elevation Myocardial Infarction, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Myocardial Infarction. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
enVast stent deployed at occlusion site as first measure to obtain reperfusion and withdraw the clot
Device: enVast stent
Treatment strategies may include balloon angioplasty, manual aspiration thrombectomy and/or coronary stenting.
Procedure: conventional treatment
In addition to conventional treatment, the treating physician will deploy as the first measure to obtain reperfusion, a enVast stent at the occlusion site in order to withdraw the clot.
Treatment strategies may include balloon angioplasty, manual aspiration thrombectomy and/or coronary stenting.
Infarct size
size assessed by measurements of CK-MB (U/L)
Time frame: At 3 days
MRI core lab Infarct size outcome
Infarct size (% of LV mass)
Time frame: At 3 days
CK
AUC for CK
Time frame: at 3 days
hsTroponin T
AUC for hsTroponin T
Time frame: at 3 days
ECG core lab outcome measures
The cumulative ST-segment deviation/elevation resolution and residual ST-segment elevation (calculated as the sum in mm of any ST-elevation and depression)
Time frame: At Procedure
Angio core lab TIMI Flow
TIMI flow
Time frame: At Procedure
Echo core lab LVEF outcome measures
Left ventricular ejection fraction (LVEF)
Time frame: At discharge (an average of 3 days)
BNP
Kinetics of B-type natriuretic peptide/NT proBNP
Time frame: At discharge (an average of 3 days)
Diuretic treatment
Need for diuretic treatment
Time frame: At discharge (an average of 3 days)
Histopathology
Histopathological evaluation of the retrieved thrombotic material (if feasible)
Time frame: During procedure
Additional MRI analysis
Additional analyses will include the assessments of hemodynamic forces and radiomics at MRI
Time frame: At procedure
Primary safety endpoint
MACE
Time frame: Day 3
CEC outcome measures
SAEs will be described according to severity and to their relationship with the study device and procedure.
Time frame: at 1-year follow-up
Other important safety endpoints
The composite of CV death, MI, and any CVA, including TIA/stroke; Death from CV causes; Overall death as stand-alone endpoint and in combination with MI, and/or CVA; Definite or probable stent thrombosis; New onset cardiogenic shock requiring inotropes or mechanical assist device; MI; Any stroke, any ischemic stroke with or without TIA; Bleeding events (access site or non-access site related) according to the BARC classification; Rehospitalization for HF in isolation and in association with CV death and/or, resuscitated cardiac arrest or ICD implantation at follow-up; Bailout use of parenteral anti-platelet agents (GPI or cangrelor) defined as any use during or after the procedure in subjects in whom no intention to use a parenteral anti-platelet agent was declared at the time of randomization; Any urgent or non-urgent TVR
Time frame: throughout 1-year follow-up
MRI Core Lab myocardial salvage index
myocardial salvage index
Time frame: At 3 days
MRI Core Lab microvascular obstruction outcome
microvascular obstruction
Time frame: At 3 days
MRI Core Lab LV volume outcome
LV volume
Time frame: At 3 days
MRI Core lab intramyocardial haemorrhage outcome
intramyocardial hemorrhage
Time frame: At 3 days
MRI core Lab left ventricle and right ventricle thrombosis outcome
left ventricle and right ventricle thrombosis
Time frame: At 3 days
MRI Core Lab RV function outcome
RV function assessment
Time frame: At 3 days
Core lab T2 mapping of the left ventricle
T2 mapping of the left ventricle
Time frame: At 3 days
MRI Core Lab wall motion score index
wall motion score index
Time frame: At 3 days
Angio Core Lab Corrected TIMI frame count
Corrected TIMI frame count
Time frame: At Procedure
Angio Core Lab Myocardial Blush Grade
Myocardial Blush Grade
Time frame: At Procedure
Echo Core Lab LV volume
LV volume
Time frame: 12 months
Echo Core Lab wall motion score index
wall motion score index,
Time frame: 12 months
Echo Core Lab wall thickness
wall thickness
Time frame: At discharge (an average of 3 days)
Echo Core lab myocardial deformation Outcome
Myocardial deformation
Time frame: At discharge (an average of 3 days)
Echo Core lab right ventricle function assessment
Right ventricle function
Time frame: At discharge (an average of 3 days)
Plan to share: Yes — Deidentified individual participant data underlying the primary and secondary efficacy and safety endpoints reported in this article (CK-MB AUC, CMR measures, biomarkers, electrocardiographic and angiographic outcomes, adverse events), after removal of direct and indirect identifiers.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Beginning 12 months (due to ongoing 12-month data collection) and ending 36 months following article publication
Access criteria: With researchers who provide a methodologically sound proposal, reviewed and approved by an independent scientific review committee, to achieve the aims of the approved proposal, via a signed data access agreement, to achieve the aims of the approved proposal, via a signed data access agreement. Proposals should be directed to [datasharing@vesalio.com]. Data requestors will be required to submit a methodologically sound research proposal; requests will be reviewed by Vesalio to confirm consistency with the aims of the approved proposal. Approved requestors will be required to sign a data access agreement prior to receiving deidentified data, which will be made available through a Vesalio-managed secure data portal
Ran from Dec 2021 to primary completion in Jun 2026, 53 months.
Of 145 interventional studies with no phase under ST Elevation Myocardial Infarction, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 64. This study's 53 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
ST Elevation Myocardial Infarction →
Vesalio